You can buy or sell Vericel and other stocks, options, ETFs, and crypto commission-free!
Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies to repair and regenerate damaged tissues and organs to normal structure and function. Its product portfolio includes MACI and Epicel. Read More The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns comprising a total body surface area of greater than or equal to 30%. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.
52 Week High
52 Week Low
Seeking AlphaMar 20
Osiris Therapeutics: Elucidating The Ramifications Of The Latest Buyout
I also share my insight on the potential buyout of Vericel and BioLife Solutions, as well as other candidates for 2019. In the long run, it's not just how much money you make that will determine your future prosperity. It's how much of that money you put to work by saving it and investing it. - Peter Lynch (stellar value and growth investor) On March 12, 2019, Osiris Therapeutics (OSIR) disclosed that Smith & Nephew (SNN) agreed to acquire the company for $660 million. At this price, the buyout equates...
Seeking AlphaMar 18
Vericel's Q4 Swoon: The Fainting Spell Is Temporary
Management's mention of ReCell complicates the Epicel picture; is it a competitor, an acquisition target, or a non-factor? (Or, perhaps all three?). The earnings day price swoon was a result of disappointing guidance and a clouding of the Epicel picture. But, should we be worried? In a word: no. We knew it had to end sometime. After four outstanding earnings day moves, including three gap-ups and third quarter 2018's spectacular +44% price explosion, on February 26, 2019, Vericel (VCEL) released its usual...
Stock Price, News, & Analysis for Vericel
Media headlines about VCEL stock have trended neutral recently, InfoTrie reports. The research group identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Vericel earned a coverage optimism score of 0.3 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of ...
Expected May 8, Pre-Market